scholarly journals Comparative Study of Psychiatric Manifestations among Type I and Type II Diabetic Patients

2017 ◽  
Vol 39 (3) ◽  
pp. 342-346 ◽  
Author(s):  
Rupesh Chaudhary ◽  
Pankaj Kumar ◽  
Akhil Chopra ◽  
Sandeep Chabbra ◽  
Parminder Singh
Keyword(s):  
Comparative Study ◽  
Diabetic Patients ◽  
Type I ◽  
Type Ii ◽  
Psychiatric Manifestations

scholarly journals Updating Experimental Models of Diabetic Cardiomyopathy

2015 ◽  
Vol 2015 ◽  
pp. 1-15 ◽  
Author(s):  
J. Fuentes-Antrás ◽  
B. Picatoste ◽  
A. Gómez-Hernández ◽  
J. Egido ◽  
J. Tuñón ◽  
...  
Keyword(s):  
Diabetic Cardiomyopathy ◽  
Type Ii Diabetes ◽  
Genetic Manipulation ◽  
Experimental Models ◽  
Diabetic Patients ◽  
Type I ◽  
Type Ii ◽  
Genetic Modifications ◽  
Human Diabetes ◽  
Contractility Of The Myocardium

Diabetic cardiomyopathy entails a serious cardiac dysfunction induced by alterations in structure and contractility of the myocardium. This pathology is initiated by changes in energy substrates and occurs in the absence of atherothrombosis, hypertension, or other cardiomyopathies. Inflammation, hypertrophy, fibrosis, steatosis, and apoptosis in the myocardium have been studied in numerous diabetic experimental models in animals, mostly rodents. Type I and type II diabetes were induced by genetic manipulation, pancreatic toxins, and fat and sweet diets, and animals recapitulate the main features of human diabetes and related cardiomyopathy. In this review we update and discuss the main experimental models of diabetic cardiomyopathy, analysing the associated metabolic, structural, and functional abnormalities, and including current tools for detection of these responses. Also, novel experimental models based on genetic modifications of specific related genes have been discussed. The study of specific pathways or factors responsible for cardiac failures may be useful to design new pharmacological strategies for diabetic patients.

scholarly journals A comparative study of type I and type II tryparedoxin peroxidases inLeishmania major

FEBS Journal ◽  
2007 ◽  
Vol 274 (21) ◽  
pp. 5643-5658 ◽  
Author(s):  
Janine König ◽  
Alan H. Fairlamb
Keyword(s):  
Comparative Study ◽  
Type I ◽  
Type Ii

scholarly journals A comparative study of the gut microbiome in Egyptian patients with Type I and Type II diabetes

PLoS ONE ◽  
2020 ◽  
Vol 15 (9) ◽  
pp. e0238764
Author(s):  
Sahar Radwan ◽  
Darby Gilfillan ◽  
Bridget Eklund ◽  
Hend M. Radwan ◽  
Nagwan G. El Menofy ◽  
...  
Keyword(s):  
Comparative Study ◽  
Gut Microbiome ◽  
Type Ii Diabetes ◽  
Type I ◽  
Type Ii ◽  
Egyptian Patients

Evaluating the Management of Diabetic Retinopathy in a Teaching Center

2002 ◽  
Vol 12 (6) ◽  
pp. 488-494
Author(s):  
N.M. Pharmakakis ◽  
I.K. Petropoulos ◽  
P.A. Peristeropoulos ◽  
C.V. Vantzou ◽  
J.X. Koliopoulos
Keyword(s):  
Diabetic Retinopathy ◽  
Laser Treatment ◽  
International Standards ◽  
Diabetic Patients ◽  
Panretinal Photocoagulation ◽  
Type I ◽  
Final Examination ◽  
Type Ii ◽  
Treatment Protocols ◽  
Teaching Center

Purpose To evaluate the efficacy of the management of diabetic retinopathy (DR) in the teaching center of the University Eye Clinic of Patras in Greece. Methods From 1989 to 1999, 302 patients with type I (5.3%) and type II (94.7%) diabetes mellitus (DM) were examined. Standard examination and treatment protocols were employed. Examinations and laser treatment were done by trainee specialists, under the supervision of the head physician (N.Ph), during their rotation in the retina and vitreous disorders outpatient department. Results At baseline examination, 17.9% of the eyes had no DR, 71.7% had nonproliferative DR, and 10.4% had proliferative DR. In 34.4%, no laser treatment followed. The other 65.6% underwent focal and/or grid laser and/or panretinal photocoagulation and/or vitrectomy. At the final examination, DR was still the same in 63.1% of the eyes, progression had occurred in 34.1%, and regression in 2.8%. Type I DM patients' eyes had a higher prevalence of proliferative DR at the final examination than type II DM eyes. There was also a significant correlation between progression of DR and duration of DM, insulin treatment for DM, and elevated glycosylated hemoglobin (HbA1c). Conclusions Having applied standard examination and treatment protocols, the efficacy of the management of our diabetic patients was consistent with international standards, even though patients were treated mostly by doctors in training.

scholarly journals ASSOCIATION OF SERUM HOMOCYSTEINE IN DIABETIC NEUROPATHY

2018 ◽  
Vol 11 ◽  
Author(s):  
Rujaswini T ◽  
Ranadheer Chowdary P ◽  
Vijey Aanandhi M ◽  
Shanmugasundaram P
Keyword(s):  
Diabetic Neuropathy ◽  
Blood Sugar ◽  
Elevated Serum ◽  
Serum Levels ◽  
Blood Parameters ◽  
P Value ◽  
Diabetic Patients ◽  
Type I ◽  
Type Ii ◽  
Serum Homocysteine

Aims and Objectives: The main aim of the study was to find out the association of serum homocysteine (HCY) in diabetic neuropathy patients. Methods: All the patients who were diagnosed with Type II diabetes mellitus will be included. Their serum levels of fasting blood sugar, postprandial blood sugar, glycated hemoglobin, and associated blood parameters will be assessed. Diabetic neuropathy will be confirmed using nerve conduction testing, electromyography, and quantitative sensory testing with clinically correlated. The serum HCY levels will be measured and correlated with other blood parameters. Results: Of 1000 patients, 46 were Type I diabetic and 954 were Type II. The prevalence of neuropathy in diabetic patients was 156. Mean serum HCY without diabetic neuropathy was 6.8+2.9 and serum HCY with diabetic neuropathy was 21.6+0.29 and p value was found to be 0.0017. The correlation between serum HCY and diabetic neuropathy was found to be 14.5 with p=0.001. Conclusion: There has been a significant increase of HCY in diabetic patients. It can be clearly seen that elevated serum HCY level has led to some of the complications of diabetic neuropathy.

Sign in / Sign up

Export Citation Format

Share Document